drugset / Trial / NCT02761512
Study to Evaluate the Safety and Efficacy of CJ-12420 in Patients With Gastric Ulcer
RandomizedParallel-groupQuadruple-blindTreatment
Summary
To demonstrate non-inferiority of CJ-12420 to lansoprazole 30 mg capsule in terms of therapeutic efficacy, and to confirm safety of CJ-12420, after once daily oral administration of CJ-12420 50 mg, 100 mg or Lansoprazole 30 mg capsule in gastric ulcer patients.
Timeline
- Start
- 2016-05
- Primary completion
- 2018-07-26
- Completion
- 2018-12-28
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Lansoprazole | Other / unclassified | 30 mg | Oral |
| Subject | Tegoprazan | Other / unclassified | 50 mg | Oral |
| Subject | Tegoprazan | Other / unclassified | 100 mg | Oral |